Yu-Ling Ni
Overview
Explore the profile of Yu-Ling Ni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang Y, Yu C, Lu M, Jou S, Lin C, Lin K, et al.
Pediatr Blood Cancer
. 2024 Jul;
71(9):e31176.
PMID: 38967585
Introduction: Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. Our aim was to identify prognostic genetic markers for patients with neuroblastoma, who were treated with the Taiwan Pediatric Oncology...
2.
Yu C, Chang Y, Wang D, Jou S, Lin C, Lin K, et al.
Sci Rep
. 2023 Jan;
13(1):490.
PMID: 36627439
Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric patients with acute lymphoblastic leukemia (ALL). NUDT15 variants have emerged as major determinants of mercaptopurine intolerance, especially in the...
3.
Yu C, Jou S, Su Y, Coustan-Smith E, Wu G, Cheng C, et al.
Cancer
. 2022 Dec;
129(5):790-802.
PMID: 36537587
Background: This study analyzed data from two consecutive protocols for children newly diagnosed with acute lymphoblastic leukemia (ALL) to determine the clinical impact of minimal/measurable residual disease (MRD) and recently...
4.
Yu C, Wu G, Chang C, Jou S, Lu M, Lin K, et al.
J Mol Diagn
. 2022 Aug;
24(11):1195-1206.
PMID: 35963521
Identification of specific leukemia subtypes is a key to successful risk-directed therapy in childhood acute lymphoblastic leukemia (ALL). Although RNA sequencing (RNA-seq) is the best approach to identify virtually all...
5.
Huang H, Yu C, Yang Y, Chang Y, Jou S, Lin K, et al.
Pediatr Blood Cancer
. 2022 Feb;
69(4):e29569.
PMID: 35119194
Background: Medulloblastoma (MB) is commonly classified into four molecular groups, that is, WNT, SHH, group 3, and group 4, for prognostic and therapeutic purposes. Methods: Here we applied immunohistochemistry (IHC)...
6.
Hsu Y, Yu C, Chen Y, Roberts K, Ni Y, Lin K, et al.
Sci Rep
. 2021 Mar;
11(1):5802.
PMID: 33707599
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukaemia (ALL), a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signalling, is associated with inferior outcomes in most childhood ALL...
7.
Yu C, Chang Y, Wang D, Jou S, Lin C, Lin K, et al.
Sci Rep
. 2020 Sep;
10(1):14400.
PMID: 32873882
Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric acute lymphoblastic leukemia. Recently, NUDT15 variants were identified as a major determinant of mercaptopurine intolerance. Two NUDT15 variants, c.36_37insGGAGTC...
8.
Yu S, Zhang H, Ho B, Yu C, Chang C, Hsu Y, et al.
Sci Rep
. 2020 Jul;
10(1):12074.
PMID: 32694622
Although the cure rate for childhood acute lymphoblastic leukemia (ALL) has exceeded 80% with contemporary therapy, relapsed ALL remains a leading cause of cancer-related death in children. Relapse-specific mutations can...
9.
Yu C, Lin T, Jou S, Lin C, Lin K, Lu M, et al.
Sci Rep
. 2020 Jul;
10(1):11501.
PMID: 32661308
Aneuploidy occurs within a significant proportion of childhood B-cell acute lymphoblastic leukemia (B-ALL). Some copy number variations (CNV), associated with novel subtypes of childhood B-ALL, have prognostic significance. A total...
10.
Ni Y, Hsieh C, Wang J, Fang K
Chem Biol Interact
. 2018 Jun;
291:137-143.
PMID: 29908167
Therapy by targeting cancer stem cells (CSCs) is an eligible method to eradicate malignant human tumors. A synthetic triepoxide derivative, teroxirone, was reported effective against the growth of human lung...